Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Corp update

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Jan 11, 2021 7:55am

166 Views

Post# 32265391

RE:RE:Corp update

I thought from a science perspective that it was well written. The timelines are frustrating, but it's COVID. The fact that they'll be submitting to the FDA within weeks was positive.

But, AGAIN with tthe $4 warrants? I know it was only 60,000 of them. But, come on. Give your team some targets to hit. I don't see this stock moving much anytime soon. I'm not getting out (and to Marky's question, I'm maybe 85% positive on ATE, with the 15% falling on Dan). This is on the cusp of Phase 3, and there just is limited momentum. It's vexing. let's what what happens this week, I'll be happy to eat my words.

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December